Advertisement
BMY or IONS or REGN
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. Ionis Pharmaceuticals (IONS) vs. Regeneron Pharmaceuticals (REGN) Stock Comparison
Key Takeaways
- BMY has shown resilience with year-to-date gains around 13% and a strong dividend yield of over 4%, supported by pipeline advancements like mezigdomide Phase III results.
- IONS delivered impressive long-term growth, up over 130% in the past year, but faced recent monthly declines amid biotech volatility and Q4 earnings updates.
- REGN maintains stability with modest year-to-date performance near flat, bolstered by robust revenue from Dupixent and EYLEA, and appears undervalued per analyst models.
- All three operate in biotech/pharma, with BMY offering diversified revenue, IONS focusing on RNA-targeted therapies, and REGN emphasizing monoclonal antibodies.
- Recent market activity highlights BMY's outperformance in shorter terms versus peers' mixed momentum.
- Valuation contrasts show BMY at a lower P/E with income appeal, while IONS and REGN trade at premiums tied to growth pipelines.
Introduction
This stock comparison examines BMY, IONS, and REGN, three prominent players in the biotechnology and pharmaceutical sectors. These companies focus on innovative therapies for oncology, neurology, and rare diseases, areas of heightened investor interest amid advancing clinical pipelines and regulatory approvals. Traders seeking momentum plays may eye recent price swings, while long-term investors could value diversified revenue streams and growth catalysts. Understanding their relative performance, business models, and market positioning aids in assessing opportunities in the current biotech landscape, where sentiment shifts with trial data and earnings.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY) is a global biopharmaceutical leader discovering, developing, and marketing therapies in oncology, immunology, and cardiovascular areas, with key products like Opdivo and Eliquis driving revenue. In recent market activity, BMY shares have gained traction, posting year-to-date advances of about 13% and monthly upticks around 11% earlier in the period, outperforming the industry. Influences include analyst price target hikes to $70 from UBS, positive Phase III data for mezigdomide in blood cancer, and a robust growth portfolio. A 4.2% dividend yield enhances appeal amid low beta of 0.27, reflecting stability. Sentiment has improved on pipeline momentum, though shares hover near $60 with a $122 billion market cap.
IONS Overview and Recent Performance
Ionis Pharmaceuticals (IONS) specializes in RNA-targeted medicines for neurological, cardiovascular, and rare diseases, with approved products like Spinraza, Wainua, and Tryngolza. Recent weeks saw IONS shares experience pressure, declining over 10% monthly and 6% year-to-date, trading around $75 with a $12 billion market cap. Factors include post-Q4 2025 earnings digestion, where financial results were reported alongside pipeline updates on programs like olezarsen for hypertriglyceridemia. Despite long-term strength—up 134% over the past year—biotech sector volatility and low beta of 0.36 have tempered momentum. Positive board transitions and strategic collaborations with Biogen and AstraZeneca support underlying sentiment.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals (REGN) develops monoclonal antibodies and biologics for eye diseases, cancer, and inflammation, powered by blockbusters like Eylea and Dupixent collaborations. In recent market activity, REGN has held steady, with flat year-to-date returns and modest 9% annual gains, shares near $775 and an $81 billion market cap. Revenue growth from core franchises and Phase 3 obesity trial positives have bolstered positioning, alongside DCF models suggesting undervaluation. Low beta of 0.40 underscores defensive traits, though quarterly revenue growth slowed to under 3%. Analyst targets average $873, reflecting optimism on pipeline and commercial strength.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of the platform's hundreds of AI trading bots, which analyze and trade thousands of tickers using diverse strategies like trend following, volatility plays, and sector momentum across timeframes from 5 minutes to daily. Only top performers suited to prevailing market conditions—such as low-to-high volatility—earn a spot here, with stats including annualized returns from +19% to +217%, win rates of 53% to 95%, and profit factors up to 9. Examples span biotech ETFs like BIB, semiconductors, and small caps. These bots offer copy trading options via signal, virtual, or brokerage agents. Explore the Trending AI Robots page to identify those aligning with your risk profile and market outlook.
Head-to-Head Comparison
BMY, IONS, and REGN share biotech exposure but diverge in models: BMY's broad pharma diversification contrasts IONS' antisense focus and REGN's antibody emphasis. Growth drivers include BMY's oncology pipeline, IONS' rare disease launches, and REGN's Dupixent royalties. Recent momentum favors BMY short-term, while IONS leads annually but lags lately; REGN offers steadiness. Risks encompass clinical setbacks for all, patent cliffs for BMY, and competition for REGN. Valuation sensitivity shows BMY cheapest on P/E with yield, versus growth premiums for peers. Sentiment tilts positive on catalysts, with low betas signaling lower volatility versus broader biotech.
Tickeron AI Verdict
Tickeron’s AI currently leans toward BMY for its consistent trend strength, pipeline catalysts like mezigdomide, income stability, and relative outperformance in recent weeks amid sector rotation. REGN ranks close for undervaluation and revenue reliability, while IONS trails on momentum dip despite long-term upside. This positioning favors probability in volatile biotech conditions, though shifts could arise with new data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 2 FA rating(s) are green whileIONS’s FA Score has 0 green FA rating(s), and REGN’s FA Score reflects 1 green FA rating(s).
- BMY’s FA Score: 2 green, 3 red.
- IONS’s FA Score: 0 green, 5 red.
- REGN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 4 TA indicator(s) are bullish while IONS’s TA Score has 4 bullish TA indicator(s), and REGN’s TA Score reflects 2 bullish TA indicator(s).
- BMY’s TA Score: 4 bullish, 6 bearish.
- IONS’s TA Score: 4 bullish, 5 bearish.
- REGN’s TA Score: 2 bullish, 7 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а -1.64% price change this week, while IONS (@Biotechnology) price change was +0.51% , and REGN (@Biotechnology) price fluctuated -1.70% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.86%. For the same industry, the average monthly price growth was -2.62%, and the average quarterly price growth was +6.54%.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.04%. For the same industry, the average monthly price growth was -3.95%, and the average quarterly price growth was +5.21%.
Reported Earning Dates
BMY is expected to report earnings on Apr 30, 2026.
IONS is expected to report earnings on May 06, 2026.
REGN is expected to report earnings on Apr 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.86% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+1.04% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BMY | IONS | REGN | |
| Capitalization | 120B | 12.4B | 79.2B |
| EBITDA | 15.2B | -273.12M | 5.82B |
| Gain YTD | 11.094 | -4.980 | -2.863 |
| P/E Ratio | 16.94 | N/A | 18.05 |
| Revenue | 48.2B | 944M | 14.3B |
| Total Cash | N/A | 2.68B | 8.61B |
| Total Debt | 47.1B | 2.07B | 2.71B |
BMY | IONS | REGN | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 68 | 12 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 5 Undervalued | 100 Overvalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 80 | 60 | 75 | |
SMR RATING 1..100 | 23 | 98 | 53 | |
PRICE GROWTH RATING 1..100 | 46 | 41 | 47 | |
P/E GROWTH RATING 1..100 | 68 | 73 | 36 | |
SEASONALITY SCORE 1..100 | 75 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (3) in the Biotechnology industry is in the same range as BMY (5) in the Pharmaceuticals Major industry, and is significantly better than the same rating for IONS (100) in the Biotechnology industry. This means that REGN's stock grew similarly to BMY’s and significantly faster than IONS’s over the last 12 months.
IONS's Profit vs Risk Rating (60) in the Biotechnology industry is in the same range as REGN (75) in the Biotechnology industry, and is in the same range as BMY (80) in the Pharmaceuticals Major industry. This means that IONS's stock grew similarly to REGN’s and similarly to BMY’s over the last 12 months.
BMY's SMR Rating (23) in the Pharmaceuticals Major industry is in the same range as REGN (53) in the Biotechnology industry, and is significantly better than the same rating for IONS (98) in the Biotechnology industry. This means that BMY's stock grew similarly to REGN’s and significantly faster than IONS’s over the last 12 months.
IONS's Price Growth Rating (41) in the Biotechnology industry is in the same range as BMY (46) in the Pharmaceuticals Major industry, and is in the same range as REGN (47) in the Biotechnology industry. This means that IONS's stock grew similarly to BMY’s and similarly to REGN’s over the last 12 months.
REGN's P/E Growth Rating (36) in the Biotechnology industry is in the same range as BMY (68) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for IONS (73) in the Biotechnology industry. This means that REGN's stock grew similarly to BMY’s and somewhat faster than IONS’s over the last 12 months.
| BMY | IONS | REGN | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 59% | 2 days ago 69% | N/A |
| Stochastic ODDS (%) | 2 days ago 52% | 2 days ago 69% | 2 days ago 58% |
| Momentum ODDS (%) | 2 days ago 53% | 2 days ago 69% | 2 days ago 46% |
| MACD ODDS (%) | 2 days ago 56% | 2 days ago 73% | 2 days ago 70% |
| TrendWeek ODDS (%) | 2 days ago 54% | 2 days ago 71% | 2 days ago 54% |
| TrendMonth ODDS (%) | 2 days ago 56% | 2 days ago 67% | 2 days ago 61% |
| Advances ODDS (%) | 3 days ago 53% | 3 days ago 67% | 11 days ago 64% |
| Declines ODDS (%) | 5 days ago 53% | 5 days ago 65% | 2 days ago 51% |
| BollingerBands ODDS (%) | 2 days ago 57% | 2 days ago 71% | 2 days ago 51% |
| Aroon ODDS (%) | 2 days ago 54% | 2 days ago 62% | 2 days ago 71% |
Advertisement
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been closely correlated with PFE. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if BMY jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To BMY | 1D Price Change % | ||
|---|---|---|---|---|
| BMY | 100% | -1.43% | ||
| PFE - BMY | 67% Closely correlated | -1.10% | ||
| MRK - BMY | 63% Loosely correlated | -1.03% | ||
| ABBV - BMY | 58% Loosely correlated | -2.10% | ||
| AMGN - BMY | 58% Loosely correlated | -1.29% | ||
| BIIB - BMY | 54% Loosely correlated | -2.34% | ||
More | ||||
REGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, REGN has been loosely correlated with ARQT. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then ARQT could also see price increases.
| Ticker / NAME | Correlation To REGN | 1D Price Change % | ||
|---|---|---|---|---|
| REGN | 100% | -2.47% | ||
| ARQT - REGN | 41% Loosely correlated | -1.47% | ||
| INCY - REGN | 40% Loosely correlated | -0.92% | ||
| SMMT - REGN | 39% Loosely correlated | +1.86% | ||
| BMRN - REGN | 39% Loosely correlated | -3.14% | ||
| IDYA - REGN | 38% Loosely correlated | -1.61% | ||
More | ||||